Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events?

Silvia Riondino,Roberto Rosenfeld,Vincenzo Formica,Cristina Morelli,Giusy Parisi,Francesco Torino,Sabrina Mariotti,Mario Roselli

DOI: https://doi.org/10.3390/cancers16071251

2024-03-24

Cancers

Abstract:The interplay between the immune system and chronic obstructive pulmonary disease (COPD) and non-small cell lung cancer (NSCLC) is complex and multifaceted. In COPD, chronic inflammation and oxidative stress can lead to immune dysfunction that can exacerbate lung damage, further worsening the respiratory symptoms. In NSCLC, immune cells can recognise and attack the cancer cells, which, however, can evade or suppress the immune response by various mechanisms, such as expressing immune checkpoint proteins or secreting immunosuppressive cytokines, thus creating an immunosuppressive tumour microenvironment that promotes cancer progression and metastasis. The interaction between COPD and NSCLC further complicates the immune response. In patients with both diseases, COPD can impair the immune response against cancer cells by reducing or suppressing the activity of immune cells, or altering their cytokine profile. Moreover, anti-cancer treatments can also affect the immune system and worsen COPD symptoms by causing lung inflammation and fibrosis. Immunotherapy itself can also cause immune-related adverse events that could worsen the respiratory symptoms in patients with COPD-compromised lungs. In the present review, we tried to understand the interplay between the two pathologies and how the efficacy of immunotherapy in NSCLC patients with COPD is affected in these patients.

oncology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the effectiveness of immunotherapy in patients with non - small - cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD), and to study whether COPD is a hidden prognostic factor for survival and a risk factor for immune - related adverse events. Specifically, the authors hope to understand the interaction between the two pathological conditions through this review, and how this interaction affects the immunotherapy effect in patients with both diseases.

It is mentioned in the article that there is a complex interaction between COPD and NSCLC. This interaction not only affects the immune system's response to tumor cells, but may also affect the efficacy of immune checkpoint inhibitors (ICIs). COPD may lead to impaired immune system function, thereby affecting the immune response to tumor cells, while NSCLC can evade immune surveillance through multiple mechanisms, such as expressing immune checkpoint proteins or secreting immunosuppressive cytokines, thus forming an immunosuppressive tumor micro - environment that promotes cancer progression and metastasis. In addition, anti - tumor treatment may also affect the immune system and aggravate the symptoms of COPD by causing lung inflammation and fibrosis. Immunotherapy itself may also lead to immune - related adverse events, which may worsen the respiratory symptoms of COPD patients.

Therefore, the paper aims to explore these complex relationships in order to provide more effective immunotherapy strategies for NSCLC patients with COPD.